{"title":"Deubiquitination of Abelson tyrosine kinase: A novel regulatory mechanism targeting non-small cell lung cancer glycolysis","authors":"Tong Yu, Shuxia Jiang, Hongli Shan","doi":"10.1002/ctd2.266","DOIUrl":null,"url":null,"abstract":"<p>In this commentary, we briefly introduce the importance of metabolic reprogramming in non-small celllung cancer (NSCLC) and the role of aberrant glycolysis processes intumorigenesis and metastasis. We further summarize the regulation of deubiquitylation modification on glycolysis-related kinases in this system. Andwe discusse the major discovery the research by He Yuanming et al. published in Clinical and Translational Medicine.Their study demonstrates targeting the USP7-c-Abl-HK2 axis represents a promising therapeutic strategt for NSCLC.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.266","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and translational discovery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In this commentary, we briefly introduce the importance of metabolic reprogramming in non-small celllung cancer (NSCLC) and the role of aberrant glycolysis processes intumorigenesis and metastasis. We further summarize the regulation of deubiquitylation modification on glycolysis-related kinases in this system. Andwe discusse the major discovery the research by He Yuanming et al. published in Clinical and Translational Medicine.Their study demonstrates targeting the USP7-c-Abl-HK2 axis represents a promising therapeutic strategt for NSCLC.